Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Revolution Medicines has entered into significant financing agreements with Royalty Pharma, including a $250 million upfront payment for tiered revenue rights from two key products: daraxonrasib (RMC-6236) and zoldonrasib (RMC-9805).
The deal includes potential additional funding tranches totaling up to $1.1 billion:
- Tranche 2: $250M tied to positive Phase 3 PDAC trial results
- Tranche 3: Up to $250M upon FDA approval
- Tranche 4: Up to $250M upon sales milestone
- Tranche 5: Up to $350M for first-line PDAC treatment success
Additionally, the company secured a $750 million term loan facility with Royalty Pharma Development Funding, structured in three tranches of $250M each. The loan bears interest at three-month SOFR (3.50% floor) plus 5.75%. This comprehensive financing package strengthens Revolution Medicines' position in advancing its RAS inhibitor pipeline, particularly for pancreatic cancer treatment.
Revolution Medicines (RVMD) General Counsel Jeff Cislini reported a sale of 1,912 shares of common stock on June 20, 2025, at a weighted average price of $39.61 per share (range: $39.26-$40.05). The transaction was executed under a pre-established 10b5-1 trading plan adopted on March 13, 2025.
Following the transaction, Cislini retains beneficial ownership of 54,093 shares, including 49,054 restricted stock units. The sale was reported through Form 4 filed on June 28, 2025, and was executed in compliance with SEC regulations. The transaction was filed by Cislini's attorney-in-fact, Jack Anders.
Revolution Medicines (RVMD) has filed a Form 144 notice for the proposed sale of securities by an insider. The filing details a planned sale of 1,912 shares of common stock with an aggregate market value of $76,346.16 through broker Morgan Stanley Smith Barney LLC.
Key transaction details:
- Securities were acquired as Restricted Stock Units from the issuer on June 15, 2025
- Planned sale date: June 20, 2025
- Trading venue: NASDAQ
- Total shares outstanding: 186,267,544
The filing also discloses that the seller, Jeffrey Todd Cislini, previously sold 1,878 shares for gross proceeds of $74,800.74 on June 16, 2025. This Form 144 represents a routine insider transaction for restricted securities, with the seller affirming no knowledge of undisclosed material adverse information about the company.
Revolution Medicines (RVMD) announced the resignation of Barbara Weber, M.D. from its Board of Directors, effective immediately prior to the company's 2025 annual meeting of stockholders scheduled for June 26, 2025. Dr. Weber will step down from her positions as:
- Board Director
- Member of the Nominating and Corporate Governance Committee
- Member of the Research & Development Committee
The resignation is directly related to the activation of a clinical study under the ongoing collaboration between Revolution Medicines and Tango Therapeutics, and not due to any disagreements with the company's operations, policies, or practices. The Form 8-K also notes that the company has registered securities including common stock (RVMD) and warrants (RVMDW) to purchase 0.1112 shares of common stock expiring in 2026 on The Nasdaq Stock Market.
Revolution Medicines (RVMD) Chief Operating Officer Margaret A. Horn reported insider trading activity on June 16, 2025. The transaction involved the sale of 3,510 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.60 to $39.83.
The sale was conducted under a pre-established Rule 10b5-1 trading plan from May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Horn maintains beneficial ownership of 150,675 shares, which includes:
- 652 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
- 79,776 restricted stock units (RSUs)
This transaction demonstrates a planned liquidation for tax purposes rather than a discretionary sale, executed under a compliant insider trading framework.
Revolution Medicines (RVMD) President and CEO Mark A. Goldsmith reported insider trading activity on June 16, 2025. The executive sold 13,496 shares at a weighted average price of $39.83 per share as part of a pre-planned Rule 10b5-1 trading plan established on May 31, 2023. The sale was executed to satisfy tax withholding obligations related to vesting restricted stock units (RSUs).
Following the transaction, Goldsmith's holdings include:
- Direct ownership: 428,720 shares (including 218,188 RSUs and 652 shares from ESPP)
- Indirect ownership: 506,452 shares total through three trusts: - 465,604 shares in family revocable living trust - 20,424 shares each in two additional trusts
The transaction was executed through multiple trades ranging from $39.60 to $39.83 per share, with the executive maintaining significant equity stake in the company through both direct and indirect holdings.
Revolution Medicines (RVMD) General Counsel Jeff Cislini reported insider trading activity on June 16, 2025. The transaction involved the sale of 1,878 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.5915 to $39.8291.
The sale was conducted under a Rule 10b5-1 trading plan established on May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Cislini's holdings include:
- Total beneficial ownership of 56,005 shares
- 49,054 RSUs included in total holdings
- 160 shares acquired through Employee Stock Purchase Plan on May 31, 2025
This transaction demonstrates a planned, automated sale for tax purposes rather than a discretionary trading decision by the insider.
Revolution Medicines (RVMD) Chief Financial Officer Jack Anders reported a significant insider transaction on June 16, 2025. The CFO disposed of 2,170 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.59 to $39.83.
The sale was conducted under a pre-established Rule 10b5-1 trading plan from May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Anders maintains beneficial ownership of 113,314 shares, which includes:
- 478 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
- 54,213 restricted stock units (RSUs)
This transaction appears to be a routine tax-related sale rather than a discretionary divestment, suggesting no significant change in the executive's long-term position in the company.
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines (NASDAQ: RVMD), reported significant insider trading activity on June 16, 2025. The transaction involved the disposition of 4,289 shares at a weighted average price of $39.83 per share.
The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Kelsey maintains beneficial ownership of 289,414 shares, which includes:
- 94,426 Restricted Stock Units (RSUs)
- 652 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
The transaction prices ranged from $39.60 to $39.83, with the reporting person agreeing to provide detailed price-specific transaction information upon request to relevant parties.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
